About A&G Pharmaceutical (http://www.agrx.net)
A&G Pharmaceutical is a theranostics company creating and developing monoclonal antibodies to cancer-specific targets as a basis for novel therapeutic and diagnostic products. A&G's therapeutics division is pursuing development of anti-GP88 and other monoclonal antibody drugs for cancer. On the diagnostics side, A&G is developing tissue and serum test kits that will improve early detection, diagnosis, and treatment of breast cancer based on GP88. One of the diagnostic products-a biopsy test kit currently in clinical trials-will also serve as a companion diagnostic to anti-GP88 immunotherapy. Early clinical studies validating the tests have been conducted at the University of Maryland Greenebaum Cancer Center and supported by grants from the Maryland Industrial Partnerships (MIPS) program and National Cancer Institute Small Business Innovation Research (SBIR) program. A&G's Precision Antibody(TM) service unit generates revenue to fund the drug development effort by providing customized antibodies to leading pharmaceutical and biotechnology companies as well as federal laboratories. A&G has raised $14 million of equity capital and is located in Columbia, Md.
About the Avon Foundation (http://www.avonfoundation.org)
The Avon Foundation, a 501(c)(3) public charity, was founded in 1955 to
improve the lives of women and their families. Now past the half century
mark, the Avon Foundation brings this mission to life through two key
areas: breast cancer and domestic violence, with support also for emergency
and disaster relief for women and their families. Through 2007 Avon glo
|SOURCE A&G Pharmaceutical|
Copyright©2007 PR Newswire.
All rights reserved